Published in HemaSphere Journal (IF = 9.1) today! Treatment outcomes in patients with large B‐cell lymphoma after progression to #CART

Great Spain+UK joint effort, big thanks to Andrea Kuhnl Pau Abrisqueta Josu Iraola Truchuelo Victor Navarro and all participating colleagues!

onlinelibrary.wiley.com/doi/full/10.10…

▶️▶️Check out new paper in Blood Journal
No RCTs of BTKi monotherapy vs ICT in R/R MCL
Malinverni et al
Large 🇪🇺🇬🇧 collaboration
BTKi monotherapy still improves survival outcomes vs ICT in 385 younger pts with later POD >24m post 1L treatment #MCL #lymsm
ashpublications.org/blood/article-…

FDA has granted accelerated approval to lisocabtagene maraleucel for adults with relapsed or refractory follicular lymphoma who have received two or more prior lines of systemic therapy.
fda.gov/drugs/resource…

#OCENewsBurst

How do BTKi-naive R/R CLL pts fare with #pirtobrutinib ?

▶️▶️Check out results from the 35 BTKi-naive high genomic risk R/R CLL pt cohort with median of 2 prior lines from BRUIN at #EHA2024

library.ehaweb.org/eha/2024/eha20…

#EHA24 looking forward to sharing phase I data for BCL2 inhibitor BGB-11417 in Waldenstrom macrogloblinemia
n=17 (10 BTKi exposed)
TEAEs anemia, COVID, neutropenia
ORR 76%, MR 41% VGPR 12%
phase II study planned
library.ehaweb.org/eha/2024/eha20…
#lymSM

Very promising indeed!

Look out for important primary analysis of UK #MCL biobank at #EHA2024
Mant et al
N=588
Active observation in 38% (N=222) of prospectively identified MCL pts.
Delaying initiation of Rx in indolent MCL does not worsen survival outcomes vs immediate Rx
Valid Mx strategy #lymsm #MCL

BTK inhibitors in CLL: second-generation drugs and beyond ashpublications.org/bloodadvances/…

Check out the new podcast on the 1L #DLBCL UK BSH - Haematology guidelines published in British Journal of Haematology
b-s-h.org.uk/guidelines/gui… #lymsm

CNS relapse risk in T-cell lymphoma. Development of the CITI score. Great work.
All we need now is some way to prevent it from happening….!
#lymsm

ashpublications.org/bloodadvances/…

Paying respects to the great man at the MCG!

Great to interview Toby Eyre promoting the benefits of science 🧬 communication!!

High rates of CD20 loss in pts relapsing after glofitamab therapy. Survival also (not surprisingly) poor. #lymsm

onlinelibrary.wiley.com/doi/10.1111/bj…

The pleasure is all mine!

Hoping our pooled data analysis is helpful to better understand long-term efficacy of acalabrutinib in higher-risk CLL Jeff Sharman Toby Eyre onclive.com/view/acalabrut… via @onclive

Fascinating article showing that outcome of lymphoid malignancy correlates with the country’s national health expenditure.

Perhaps not surprising but underscores need to access new evidence based developments. #lymsm

thelancet.com/journals/lanon…

What are some of the key factors to consider when choosing a treatment option for patients with CLL? 🤔

We sat down with Piers Patten of King's College London at #BSH2024 to hear his thoughts:
🎥 ow.ly/BghH50Rvytf

#CLLsm #Leukemia #Leusm #HemOnc BSH - Haematology

CAR T-cell Therapy in Mantle cell with sCNS Involvement.
Active disease PFS only 25%, without active disease about 33%. Perhaps needs post CT maintenance?
Mazyar Shadman, MD MPH Gulrayz Ahmed Farrukh Awan Tim Fenske Madiha Iqbal MD Mohamed Kharfan-Dabaja, MD, MBA MCW Cancer Center #lymsm #CART
ashpublications.org/bloodadvances/…

Sonrotoclax is a potent and selective BCL2 inhibitor that is also effective in venetoclax-resistant BCL2 mutants both in vitro and in vivo. ow.ly/gNeo50RvWeb #lymphoidneplasia